Angiotensin-Converting Enzyme Inhibition Delays Onset of Glucosuria With Regression of Renal Injuries in Genetic Rat Model of Non-Insulin-Dependent Diabetes Mellitus
- 1 December 1998
- journal article
- research article
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 3 (4) , 327-335
- https://doi.org/10.1177/107424849800300408
Abstract
Background: The Otsuka Long-Evans Tokushima Fatty (OLETF) rat is a new genetic model of non-insulin-dependent diabetes mellitus (NIDDM). We investigated whether angiotensin inhibition influences the onset of NIDDM and brings about a regression of renal injury in diabetes mellitus. Methods and Results: Six-week-old OLETF rats were treated with the angiotensin-con verting enzyme (ACE) inhibitors imidapril or enalapril for 16 weeks. Systolic blood pres sure is increased in an age-dependent manner in OLETF rats. In this study, the elevation in systolic blood pressure was dose-dependently reduced by ACE inhibitor treatment. In OLETF rats, plasma concentrations of insulin and glucose increased and the glucosuria occurred at the age of 22 weeks. Simultaneously, OLETF rats exhibited proteinuria and nodular lesions in glomeruli. The ACE inhibitor treatment almost completely reduced glu cosuria, and also decreased plasma concentrations of insulin and glucose in OLETF rats. ACE inhibitor treatment lessened the proteinuria and attenuated morphologically the severity of nodular lesions in OLETF rats. Moreover, increases in plasminogen activator inhibitor 1 (PAI-1) in OLETF rats were reduced by the ACE inhibitor treatment, and the improvement of glomerular lesions was related to decreases of PAI-1 and angiotensin II levels in plasma but not to improvement of glucose metabolism. Conclusions: ACE inhibitors delay onset of NIDDM with attenuation of kidney injury. The regression of kidney lesions is probably due to angiotensin reduction but not to glucose metabolism per se. ACE inhibitor drug therapy may be useful in preventing NIDDM and the subsequent renal injury in patients with NIDDM.Keywords
This publication has 29 references indexed in Scilit:
- Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibitionKidney International, 1997
- Role of Bradykinin in Insulin Sensitivity and Blood Pressure Regulation During HyperinsulinemiaHypertension, 1995
- Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats.Hypertension, 1994
- Insulin and hypertensionJournal Of Hypertension, 1994
- Little or No Expression of the Cholecystokinin-A Receptor Gene in the Pancreas of Diabetic Rats (Otsuka Long-Evans Tokushima Fatty=OLETF Rats)Biochemical and Biophysical Research Communications, 1994
- Bradykinin-mediated effects of ACE inhibitionKidney International, 1992
- A Comparison of the Effects of Hydrochlorothiazide and Captopril on Glucose and Lipid Metabolism in Patients with HypertensionNew England Journal of Medicine, 1989
- Plasma Angiotensin-(1-8) Octapeptide Measurement to Assess Acute Angiotensin-Converting Enzyme Inhibition with Captopril Administered Parenterally to Normal SubjectsJournal of Cardiovascular Pharmacology, 1988
- Insulin Resistance in Essential HypertensionNew England Journal of Medicine, 1987
- Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl ratsKidney International, 1984